Rearrangements of the MLL (mixed lineage leukemia) gene are associated with pediatric, adult and therapy-related acute leukemias of both myeloid (AML) and lymphoid lineage (ALL). 1, 2 Today, 55 partner genes have been characterized at the molecular level and additional 36 genetic loci have been identified by cytogenetics. 3 The most common translocation partner genes are AFF1 (AF4), MLLT3 (AF9), MLLT1 (ENL), MLLT10 (AF10), MLLT4 (AF6) and ELL, respectively. These partner genes account for about 80% of all rearrangements of the MLL gene. 3, 4 The MLLT1 gene is a frequent translocation partner and accounts for about 5% of all MLL rearrangements. In most cases, the MLLT1 gene is rearranged with the MLL gene via a balanced reciprocal translocation, but also more complex aberrations have been described including three way translocations. [5] [6] [7] The t(11;19)(q23;p13.3) has been identified in patients with lymphoid, myeloid and biphenotypic malignancies. Therapy-related translocations between MLL and MLLT1 are very rare, and so far only one t-AML case has been described in the literature. 8 Although MLL rearrangements are associated with a dismal outcome, two distinct subsets within the group of MLL-MLLT1 fusions have been identified that seem to have a good prognosis: ALL patients between 1and 9 years and patients with T-lineage ALL. 9 The MLLT1 gene encodes a protein with a high homology to the MLLT3 gene. 10, 11 It has been shown that the DNA-binding motifs encoded by the MLL gene and the C-terminal domain of MLLT1 are necessary and sufficient for the transforming activity of the MLL-MLLT1 fusion protein. 12 Retroviral transduction of MLL-MLLT1 transgenes into hematopoietic progenitors was sufficient to cause leukemia in mice. 13, 14 A translocator mouse model has also been developed in which de novo chromosomal translocations of the Mll and Mllt1 loci can be induced during hematopoietic development. 15 After induction of chromosomal translocations, a rapid development of myeloid leukemias has been observed. Moreover, the Mll-Mllt1 fusion protein was able to genetically instruct lymphoid progenitor cells to develop into myeloid cells, demonstrating that this Mll-Mllt1 fusion protein has the ability to influence hematopoietic lineage commitment. 16 The human MLL-MLLT1 fusion protein was shown to be required for the immortalization of murine myeloid progenitors by aberrantly sustaining a specific 'Hox code' which is reflected by the upregulation of the HoxA4-HoxA11 genes, respectively. 17 Here, we investigated the genomic breakpoints of 40 acute leukemia patients carrying the t(11;19)(q23;13.3) chromosomal translocation. Bone marrow or peripheral blood of 40 different leukemia patients were collected over a period of 2 years at different European study centers (Interfant-99, GMALL and I-BFM). The patients separate into 22 pediatric (ALL: 20; AML: 2) and 18 adult leukemia patients (ALL: 17; AML: 1). For all patients, the genomic fusions sites were successfully analyzed by a long-distance-inverse-(LDI)-polymerase chain reaction (PCR). 18 Detailed analyses of the breakpoint fusion sequences revealed the presence of filler-DNA (nucleotides not present on both chromosomes) and mini-direct-repeats at the breakpoint junctions. Filler-DNA, mini-direct-repeats and the insertion of DNA fragments are typical hallmarks for non-homologous DNA endjoining DNA repair processes at the molecular basis of each of these chromosomal translocation. 19 In one patient, (P04-324), the insertion of a 848-bp DNA fragment derived from the GNA15 gene (guanine nucleotide-binding protein a-15 subunit) was observed at the breakpoint junction. The GNA15 gene is located about 3.1 Mbp telomer to the MLLT1 gene at 19p13.3 and has an opposite transcriptional orientation on the chromosome with regard to the MLLT1 gene. All results were summarized in the Supplementary Tables 1 and 2 .
The distribution of chromosomal breakpoints within the MLL gene were scattered between intron 9 and 11, respectively. Breakpoints were identified in MLL intron 9 (7/40; 17.5%), intron 10 (7/40; 17.5%), exon 11 (2/40; 5%) and predominantly in intron 11 (24/40 ¼ 60%). To our surprise, only 50% of the analyzed breakpoints were located within the MLLT1 gene (intron 1: 18; intron 3: 1; intron 6: 1). The remaining 50% were located up to 26 kb upstream of the MLLT1 gene, within the intergenic region between ASAH3 and MLLT1 (see Figure 1a) . Therefore, 95% of all genomic breakpoints cluster in a 35 kb region (26 kb intergenic region þ 9 kb MLLT1 intron 1). As the intergenic region between ASAH3 and MLLT1 gene contains 26 Alu repetitive elements, we also analyzed whether they are preferential recombination hot spots. However, no such preference was found because only one out of 40 patients had a recombination site located within an Alu repetitive element.
To analyze whether patients with a breakpoint located outside of the MLLT1 transcription unit produce functionally fused chimeric mRNAs, we analyzed all patients where total RNA was made us available for MLL-MLLT1 fusion transcripts (n ¼ 9). In all cases, a chimeric MLL-MLLT1 fusion transcript was obtained (see Figure 1b, lanes 1-5) .
Thus, the MLL gene was fused to the intact MLLT1 gene via transcriptional readthrough and a subsequent splice event, or by trans-splicing. Both ways, the chimeric MLL fusion mRNA is only produced at the RNA level, designating this process as 'spliced MLL fusion'. A second consequence is that no genetic haploinsufficiency exists for the MLLT1 gene in these patients, as the MLLT1 gene remains untouched by the recombination process. A third consequence is that no reciprocal MLLT1 Á MLL fusion transcript can be transcribed because the promoter-less 3 0 -portion of the MLL gene is located downstream of the ASAH3 gene. Thus, the oncogenic denominator of all t(11;19)(q23;p13.3) leukemia patients is the MLL-MLLT1 fusion transcript. In fact, the MLL-MLLT1 fusion protein has been shown to be sufficient for the initiation and maintenance of a leukemia disease phenotype in several mouse model systems. [12] [13] [14] 20, 21 Noteworthy, three patients with a breakpoint upstream of the MLLT1 gene especially skipped MLL exon 11, although this exon was present at the genomic level (see Figure 1b, lanes 1-3) . This skipping of MLL exon 11 was not observed in cases, where the MLL gene was fused directly to the MLLT1 gene (Figure 1b, lanes 6-9) . This may simply be coincidence, and therefore, further studies are needed to confirm this finding by analyzing t(11;19)(q23;p13.3) leukemia patients at the genomic and RNA level. Unfortunately, we had only limited access to RNA samples, and thus, we could not confirm that this observation is true for the additional 12 patients with breakpoints located upstream of the MLLT1 gene and a breakpoint within MLL intron 11.
However, two patients with a T-ALL disease phenotype have been reported to carry a genomic deletion of MLL exon 11.
22 MLL exon 11 encodes part of the first PHD finger and binding of the CYP33 protein to the PHD region of MLL has been demonstrated. 23 Deregulated expression of CYP33 or altered binding is associated with altered Hox gene expression, indicating that this region of the MLL protein is presumably of interest.
Spliced MLL fusions were already described for two single leukemia patients. One patient with a t(11;15) translocation showed an additional spliced fusion to another gene located on chromosome 15, namely the MPFYVE gene. This led to an MLLAF15q14 and an MLL-MPFYVE fusion transcript in that particular patient. 24 In another patient with an intrachromosomal 11q deletion a genomic fusion of the MLL gene with the 3 0 -NTR of the TIRAP gene was identified. Transcription of the MLL-TIRAP fusion gene was never observed, because the MLL mRNA was spliced to another gene, the DCPS gene, that is located about 5 kb downstream of the TIRAP gene. 18 Thus, in single patients this phenomenon has already been observed, however, the high frequency of about 50% spliced MLL fusions in t(11;19)(q23;p13.3) leukemia patients has neither been expected nor previously shown. Therefore, we conclude that transcriptional read-through and subsequent splicing -or transsplicing -to other transcription units is a novel property of disrupted MLL genes in order to create functional MLL fusionsat least at the mRNA level. This extends our current knowledge on mechanisms by which the MLL gene can be converted into an oncogene. Further studies will help to investigate the remaining question whether these two groups of t(11;19)(q23;p13.3) leukemia patients behave differently under treatment or have any significant differences in outcome.
We 
